Chemours Q2 Sales Miss, But Adjusted EBITDA Beats; Maintains 2026 Outlook
CC sits 51% above its 52-week low of $10.44.
Summary
Chemours reported flat Q2 sales of $1.60B, missing the $1.65B consensus, while adjusted EPS of $0.42 met expectations and adjusted EBITDA of $247M beat by $9M. The GAAP loss of $1.81 per share reflects ongoing financial strain, but the company maintained its 2026 adjusted EBITDA outlook of $775M-$825M and guided Q3 adjusted EBITDA to $175M-$205M. Volume declines in TSS aftermarket refrigerants and APM due to a line closure weighed on the top line, partially offset by pricing actions. This follows the June PFAS settlement with the EPA and West Virginia DEP, which added to litigation and environmental charges. The maintained full-year guidance and EBITDA beat may provide some relief, but the sales miss and volume weakness keep pressure on the stock.
At the time of this announcement, CC was trading at $15.80 on NYSE in the Manufacturing sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $10.44 to $28.67. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.